CD99 and acute myeloid leukemia: In addition, monoclonal antibodies (mAbs) targeting CD99 can induce cell death of MDS HSPCs and AML in vitro, and exhibit antileukemic activity in AML xenografts, without significantly depleting normal HSCs.